Replies

” Inasmuch as neutralizing antibodies overwhelm facilitating antibodies, ADE is not a concern.”

“this potential risk has been cleverly anticipated before the massive use of Covid-19 vaccines6, the ability of SARS-CoV-2 antibodies to mediate infection enhancement in vivo has never been formally demonstrated. However, although the results obtained so far have been rather reassuring, to the best of our knowledge ADE of Delta variants has not been specifically assessed.”

coulda woulda shoulda

Delta was born in October 2020 in India, well before vaccines were developed much less distributed in India. ADE in Delta hasn’t been ‘specifically assessed’ because nobody’s reporting it as an issue. Those who have been vaccinated and get infected with Delta, generally have mild infections, depending on individual antibody production.

Are there people who get reinfected twice after vaccination ? Has anyone seen any stories? The bigger danger is the virus itself mutating its immune escape devices like it’s been doing all along.

Against Delta:

Pfitzer (July 21 New England Journal of Medicine) 88% effective against hospitalization, down from 93% ; in the UK 93% effective down from 94%; Scotland 79% (Lancet); Canada 87%; Israel 67% and 93% against death, adjusted in late July to 44% against symptoms but still 88% hospitalization and 93% death. France (July 8 study), one dose 13%, two doses 94%

Moderna: Canada 70% one dose 95% two doses down from 97%

AZ - England 79% and 96% (Public Health England); one dose 13% two doses 96% (July 8 study)

J&J - one dose - 87% effective hospitalization, especially robust against Delta (phase 3 Ensemble study) across all demographics; 71% and 96% (South Africa Sisonke study 500K subjects)

Novavax - (recombinant nanoparticle vaccine) England 89% overall with 86% against alpha and 96% against all other variants